Description
+ Include: 52 videos + 38 pdfs, size: 4.62 GB
+ Target Audience: oncologist
+ Sample video: contact me for sample video
+ Information:
- Start date: 04 Oct 2023
- End date: 06 Oct 2023
- Location: Paris, France
The Molecular Analysis for Precision Oncology Congress (MAP) 2023 took place from 4 to 6 October 2023 in Paris, France.
MAP is a congress designed to provide the latest data in the field of precision oncology, molecular profiling and personalised medicine.
The focus of the event is to create a bridge between basic scientists, or people working on new technologies, and medical doctors and healthcare providers.
Our globally recognised experts in clinical and precision oncology welcomed delegates for three days of discussions on the latest discoveries in precision medicine, cancer-stromal interactions, clonal evolution, metastatic dissemination and drug response and resistance.
The MAP Congress is the result of a solid partnership among Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and Unicancer, all committed to offering the best care to people with cancer worldwide, through oncology education and research.
The partner societies had the pleasure of introducing a special day on 6 October 2023: “RoadMAP to the Clinic 2023: From organ specific to biomarker driven drug development and approval”. Society experts and stakeholders from the scientific community, regulatory and HTA authorities, patient advocates, methodological experts and pharmaceutical industry representatives participated in sessions comprising lectures and brainstorming discussion on this year’s theme ”How to transform development and registration of precision therapeutics in oncology from organ-specific to histology-agnostic and biomarker driven approvals”, in order to achieve molecularly informed, resource-rational and timely enrichment of the therapeutic armamentarium for our patients.
+ Topics:
Clonal evolution Identifying the drivers of cancer and clonal hematopoiesis by evolution-based methods.mp4
Clonal evolution Identifying the drivers of cancer and clonal hematopoiesis by evolution-based methods.pdf
Clonal evolution Mathematical modelling to develop insights into cancer evolution.mp4
Clonal evolution Mathematical modelling to develop insights into cancer evolution.pdf
Clonal evolution Q&A.mp4
Conference Calendar – Molecular Analysis for Precision Oncology Congress 2023.pdf
Ecology of cancer Cancer-type-specific fungal ecologies and bacteriome.mp4
Ecology of cancer Cancer-type-specific fungal ecologies and bacteriome.pdf
Ecology of cancer Q&A.mp4
Gordon Peters keynote lecture Introduction to the keynote lecture.mp4
Gordon Peters keynote lecture Introduction to the keynote lecture.pdf
Immunotherapy Breast cancer Immunotherapy- Role of tissue resident memory cells.mp4
Immunotherapy Breast cancer Immunotherapy- Role of tissue resident memory cells.pdf
Immunotherapy Q&A.mp4
Immunotherapy T cell eosinophil crosstalk during response to immune checkpoint blockade.mp4
Immunotherapy T cell eosinophil crosstalk during response to immune checkpoint blockade.pdf
Keynote lecture Role of neutrophils in tumour metastases.mp4
Keynote lecture Role of neutrophils in tumour metastases.pdf
Molecular characterisation Multi modal single cell characterization of cancers and WGS.mp4
Molecular characterisation Multi modal single cell characterization of cancers and WGS.pdf
Molecular characterisation Q&A.mp4
Molecular characterisation Single cell epigenomics in tumour progression.mp4
Molecular characterisation Single cell epigenomics in tumour progression.pdf
Molecular characterisation Spatial resolution in molecular characterization- Impact of cancer heterogeneity in treatment.mp4
Molecular characterisation Spatial resolution in molecular characterization- Impact of cancer heterogeneity in treatment.pdf
New trial designs, new paths to drug registration Biomarker-driven immunotherapies- How relevant is being tumour type-specific.mp4
New trial designs, new paths to drug registration Biomarker-driven immunotherapies- How relevant is being tumour type-specific.pdf
New trial designs, new paths to drug registration DRUP (Drug Repurposing) trial and beyond- Learning from DRUP 1.0.mp4
New trial designs, new paths to drug registration DRUP (Drug Repurposing) trial and beyond- Learning from DRUP 1.0.pdf
New trial designs, new paths to drug registration Fast-tracking preclinical research to pan-cancer trials- Success stories and less so.mp4
New trial designs, new paths to drug registration Fast-tracking preclinical research to pan-cancer trials- Success stories and less so.pdf
New trial designs, new paths to drug registration Introduction.mp4
New trial designs, new paths to drug registration Introduction.pdf
New trial designs, new paths to drug registration Pre-clinical development of targeted agents- Change of mindset from tumour.mp4
New trial designs, new paths to drug registration Pre-clinical development of targeted agents- Change of mindset from tumour.pdf
New trial designs, new paths to drug registration Q&A 1.mp4
New trial designs, new paths to drug registration Q&A 2.mp4
New trial designs, new paths to drug registration Towards harmonised design and interpretation of histology agnostic, biomarker driven trials.mp4
New trial designs, new paths to drug registration Towards harmonised design and interpretation of histology agnostic, biomarker driven trials.pdf
Proffered Paper session 1 Are targeted therapies effective in the relapsed or metastatic cancer setting A Cochrane meta-analysis.mp4
Proffered Paper session 1 Are targeted therapies effective in the relapsed or metastatic cancer setting A Cochrane meta-analysis.pdf
Proffered Paper session 1 Deciphering resistance mechanisms in cancer- Insights from the final report of MATCH-R study with focus on molecular drivers.mp4
Proffered Paper session 1 Deciphering resistance mechanisms in cancer- Insights from the final report of MATCH-R study with focus on molecular drivers.pdf
Proffered Paper session 1 Dissecting intratumoral heterogeneity in localized HR+HER2- breast cancer using single-cell DNA sequencing (scDNA-seq).mp4
Proffered Paper session 1 Dissecting intratumoral heterogeneity in localized HR+HER2- breast cancer using single-cell DNA sequencing (scDNA-seq).pdf
Proffered Paper session 1 Invited discussant 1.mp4
Proffered Paper session 1 Invited discussant 1.pdf
Proffered Paper session 1 Invited discussant 2.mp4
Proffered Paper session 1 Invited discussant 2.pdf
Proffered Paper session 1 Q&A 1.mp4
Proffered Paper session 1 Q&A 2.mp4
Proffered Paper session 2 Invited discussant 1.mp4
Proffered Paper session 2 Invited discussant 1.pdf
Proffered Paper session 2 Invited discussant 2.mp4
Proffered Paper session 2 Invited discussant 2.pdf
Proffered Paper session 2 Q&A.mp4
RoadMAP to the Clinic 2023 The current landscape of research and development (R&D) and approval of precision therapeutics- The challenge of optimisation.mp4
RoadMAP to the Clinic 2023 The current landscape of research and development (R&D) and approval of precision therapeutics- The challenge of optimisation.pdf
RoadMAP to the Clinic 2023 Welcome and objectives.mp4
Sarcoma Clinical utility of next-generation sequencing in sarcomas.mp4
Sarcoma Clinical utility of next-generation sequencing in sarcomas.pdf
Sarcoma Immunotherapy for sarcomas.mp4
Sarcoma Immunotherapy for sarcomas.pdf
Sarcoma Q&A.mp4
Technology of radiation FLASH radiation therapy.mp4
Technology of radiation FLASH radiation therapy.pdf
Technology of radiation Molecular determinants of radiosensitivity and implications on multi-modality therapy.mp4
Technology of radiation Molecular determinants of radiosensitivity and implications on multi-modality therapy.pdf
Technology of radiation Q&A.mp4
Technology of radiation Real-time, image guided, adaptive radiotherapy- Advances in precision radiation oncology.mp4
Technology of radiation Real-time, image guided, adaptive radiotherapy- Advances in precision radiation oncology.pdf
The next wave of pan-cancer clinical trials Panel discussion.mp4
The next wave of pan-cancer clinical trials The future of the tissue agnostic targets.mp4
The next wave of pan-cancer clinical trials The future of the tissue agnostic targets.pdf
The next wave of pan-cancer clinical trials Wrap-up and roadmap for actions.mp4
The next wave of pan-cancer clinical trials Wrap-up and roadmap for actions.pdf
Tumour microenvironment Overview and microenvironment of metastasis.mp4
Tumour microenvironment Overview and microenvironment of metastasis.pdf
Tumour microenvironment Q&A.mp4
Welcome to the MAP Congress 2023.mp4
Welcome to the MAP Congress 2023.pdf
What are the current roadblocks to histology Design and running of biomarker-driven pan-cancer trials- Methodological perspectives.mp4
What are the current roadblocks to histology Design and running of biomarker-driven pan-cancer trials- Methodological perspectives.pdf
What are the current roadblocks to histology Q&A.mp4
What are the current roadblocks to histology The patient perspective on pan-cancer trials and access to drugs.mp4
What are the current roadblocks to histology The patient perspective on pan-cancer trials and access to drugs.pdf
What are the current roadblocks to histology The regulator perspective on biomarker and test development (EMA).mp4
What are the current roadblocks to histology The regulator perspective on biomarker and test development (EMA).pdf
What are the current roadblocks to histology The regulator perspective on pan-cancer drug development (FDA).mp4
What are the current roadblocks to histology The regulator perspective on pan-cancer drug development (FDA).pdf
Reviews
There are no reviews yet.